Incidence of Radioiodine Induced Graves' Disease in Patients with Multinodular Toxic Goiter

Abstract

In this study, we assessed the incidence of Graves' disease (GD) following radioiodine therapy (RIT) in a large cohort of well characterized patients with autonomy in comparison to the clinical course of control patients with thyroidal autonomy not definitively treated with (131)I or surgery. 622 consecutive patients were treated with (131)I for autonomy (unifocal: n = 321; multifocal: n = 199; disseminated: n = 102) and followed up for at least 6 months post RIT. 108 consecutive patients with autonomy not definitively treated (unifocal: n = 49; multifocal: n = 42; disseminated: n = 11) followed up for at least 6 months served as controls. Initial evaluation and follow-up included determination of FT3, FT4, TSH, autoantibodies against the thyroid peroxidase (anti-TPO) and TSH-receptor antibodies (TRAb) by highly sensitive radio receptor-assay, quantitative thyroid scintigraphy and sonography. After 6 months, GD was newly diagnosed in 1/321 patients with unifocal autonomy, in 1/199 patients with multifocal autonomy and in 0/108 control patients. In patients with disseminated autonomy (group C), GD was diagnosed significantly more often compared to the other groups (5/102 patients; 4,1 %; p < 0.05). In conclusion, RIT may induce Graves' disease in a few cases with toxic multinodular goiter. The incidence in this population is small. Compared with patients suffering from uni- or multifocal autonomy, subjects with disseminated autonomy have a more than tenfold higher risk for the development of GD.

Thyroid metastasis of endometrial carcinosarcoma associated with Graves' disease

“…Thyroid destruction and release of thyroid autoantigen may trigger autoimmunity in long-term follow-up. Graves' disease after radioactive iodine treatment for toxic nodular goiter was reported previously [12]. But it is highly unlikely that destructive thyroiditis by metastatic thyroid tumor contributed to thyroid autoimmunity in our patient when the rapid clinical course is considered.…”

2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis

“…GD might develop after RAI for TMNG in up to 4% of patients (280). Such patients develop worsening hyperthyroidism within a few months of RAI therapy.…”

Epidemiology of environmental exposures and human autoimmune diseases: Findings from a National Institute of Environmental Health Sciences Expert Panel Workshop

“…There is convincing evidence that external radiation treatment for cancer increases the risk of autoimmune thyroiditis and GD, especially in treatment for cancers of the neck region (e.g., Hodgkin disease, thyroid cancer, head and neck cancers) [61, 62]. Radioiodine therapy for nodular toxic goiter or toxic adenoma can cause GD [63]. Overt hypothyroidism occurs in about 20-30% of patients treated with radiotherapy, and the effect is dose dependent.…”